Wells Fargo raises Hinge Health stock price target on strong yield

Hinge Health reported 3Q 2026 revenue of $234.97M, up year-over-year, driven by member retention and growth. EPS was $0.66. Gross margin improved to 87% from 82%. Client base grew to 3,270. The company launched a Migraine Care Program and acquired Cylinder Health.

Canaccord raised Hinge Health's (HNGE) price target to $134 from $105, citing strong Q3 results. Revenue grew 52% YoY to $235M, beating estimates. Non-GAAP operating income was $77.2M, also above expectations. The company raised its 2026 revenue and income guidance. Other analysts, including Wells Fargo and Needham, also increased their price targets.

Needham raised its price target for Hinge Health (NYSE:HNGE) to $135 from $115, citing strong client growth and quarterly performance. The company reported 28% year-over-year client growth, 50% revenue increase, and 154% stock return over six months. Q3 revenue was $235 million, up 52% year-over-year, with EPS of $0.66 beating estimates. Wells Fargo also raised its target to $132, noting strong margins and revenue growth.

Wells Fargo increased its price target for Hinge Health (HNGE) to $132 from $103, citing strong Q3 results. Revenue was $235M, up 52% YoY, and adjusted EBIT was $77M, both exceeding estimates and guidance. The company also raised its 2026 revenue outlook. HNGE's stock is near its 52-week high, with a 149% YTD return.

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, with an 88% gross margin and $77M operating income. The company forecasted 2026 revenue of $879M-$881M and aims to launch an integrated GI program by summer 2027, according to management.